Dr. David J. Cahn, MD
Urology (Urology Physician)
- Medicare participating
At a glance
- Medical school
- Albert Einstein College of Medicine of Yeshiva University (1990)
- Years since graduation
- 36
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 361
Licensed in Colorado since 1996, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1990Medical school: Albert Einstein College of Medicine of Yeshiva University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Urology Physician primary
CO license 35416 (first issued 1996; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Centura Health-St Anthony Hospital Lakewood, CO
Medical groups
- Advanced Urology PLLC (59 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 361
- Services billed
- 4,228
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, denosumab, 1 mg | 1,620 | 11 |
| Established patient office or other outpatient visit, 30-39 minutes | 209 | 144 |
| Established patient office or other outpatient visit, 20-29 minutes | 208 | 171 |
| Automated urinalysis test | 124 | 109 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 94 | 33 |
| Ultrasound measurement of bladder capacity after voiding | 89 | 79 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 85 | 11 |
| Diagnostic exam of bladder and urethra using an endoscope | 62 | 58 |
| New patient office or other outpatient visit, 45-59 minutes | 57 | 57 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 37 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Finasteride Other prescribers in Golden, CO | 468 |
| Tamsulosin Hcl Other prescribers in Golden, CO | 422 |
| Abiraterone Acetate | 139 |
| Orgovyx (relugolix) | 137 |
| Prednisone Other prescribers in Golden, CO | 97 |
| Myrbetriq (mirabegron) Other prescribers in Golden, CO | 75 |
| Gemtesa (vibegron) Other prescribers in Golden, CO | 48 |
| Erleada (apalutamide) | 47 |
| Solifenacin Succinate Other prescribers in Golden, CO | 43 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Golden, CO | 35 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 22 companies reported 80 payments worth $22,235 in total to this clinician.
| Janssen Biotech, Inc. | $12,865 |
|---|---|
| Janssen Scientific Affairs, LLC | $5,681 |
| GlaxoSmithKline, LLC. | $2,400 |
| Sumitomo Pharma America, Inc. | $162 |
| Urogen Pharma, Inc. | $151 |
| Dendreon Pharmaceuticals LLC | $145 |
| Boston Scientific Corporation | $103 |
| Tolmar, Inc. | $90.18 |
| Consulting Fee | $10,014 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $6,160 |
| Travel and Lodging | $3,407 |
| Food and Beverage | $2,655 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. May 9, 2025 | Consulting Fee | $4,024 |
| Janssen Biotech, Inc. Nov 18, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $3,300 |
| Janssen Biotech, Inc. Oct 24, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $2,860 |
| GlaxoSmithKline, LLC. Apr 2, 2025 | Consulting Fee | $2,400 |
| Janssen Scientific Affairs, LLC Oct 22, 2025 | Consulting Fee | $1,410 |
| Janssen Scientific Affairs, LLC Apr 27, 2025 | Consulting Fee | $1,363 |
| Janssen Biotech, Inc. Apr 27, 2025 | Consulting Fee | $818 |
| Janssen Scientific Affairs, LLC Mar 9, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $497 |
| Janssen Scientific Affairs, LLC Apr 9, 2025 | Travel and Lodging travel to GOLDEN, CO · in-kind | $450 |
| Janssen Scientific Affairs, LLC Apr 9, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $444 |
All 21 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Janssen Scientific Affairs, LLC Dec 9, 2025 | Travel and Lodging ERLEADA · Oncology · travel to DENVER, CO · in-kind | $14.00 |
| Janssen Biotech, Inc. Nov 18, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $3,300 |
| Janssen Biotech, Inc. Nov 14, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Las Vegas, NV · in-kind | $172 |
| Janssen Biotech, Inc. Oct 30, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Greenwood Village, CO | $25.20 |
| Janssen Biotech, Inc. Oct 24, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $2,860 |
| Janssen Scientific Affairs, LLC Oct 22, 2025 | Consulting Fee | $1,410 |
| Janssen Biotech, Inc. Oct 16, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Las Vegas, NV · in-kind | $423 |
| Janssen Biotech, Inc. May 9, 2025 | Consulting Fee | $4,024 |
| Janssen Scientific Affairs, LLC May 9, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $174 |
| Janssen Scientific Affairs, LLC Apr 27, 2025 | Consulting Fee | $1,363 |
| Janssen Biotech, Inc. Apr 27, 2025 | Consulting Fee | $818 |
| Janssen Biotech, Inc. Apr 23, 2025 | Travel and Lodging travel to DALLAS, TX · in-kind | $148 |
| Janssen Biotech, Inc. Apr 23, 2025 | Travel and Lodging travel to DALLAS, TX · in-kind | $131 |
| Janssen Scientific Affairs, LLC Apr 9, 2025 | Travel and Lodging travel to GOLDEN, CO · in-kind | $450 |
| Janssen Scientific Affairs, LLC Apr 9, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $444 |
| GlaxoSmithKline, LLC. Apr 2, 2025 | Consulting Fee | $2,400 |
| Janssen Biotech, Inc. Mar 27, 2025 | Travel and Lodging travel to DALLAS, TX · in-kind | $233 |
| Janssen Scientific Affairs, LLC Mar 9, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $497 |
| Janssen Scientific Affairs, LLC Mar 9, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $323 |
| Janssen Scientific Affairs, LLC Mar 9, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $194 |
| Janssen Scientific Affairs, LLC Mar 9, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $179 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 30 industry-funded studies in 2025, from 8 companies. The companies reported $3,894,039 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate …
Janssen Research & Development, LLC - A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Ca…
AstraZeneca Pharmaceuticals LP - A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasiv…
Merck Sharp & Dohme LLC - A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy
Janssen Research & Development, LLC - A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Pros…
Janssen Research & Development, LLC - A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible …
Janssen Research & Development, LLC - A phase 3b,open label,single arm,multi center,US study of bacillus calmette guerin bcg administered in combination with durvalumab in adult bcg naive,high risk non muscle invasive bladder cancer participants patapsco
AstraZeneca Pharmaceuticals LP - BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical
Bayer HealthCare Pharmaceuticals Inc. - A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Ri…
Janssen Research & Development, LLC - A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Pros…
AstraZeneca UK Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.